Update regarding COVID-19

In view of the general uncertainty and measures put in place to reduce the spread of COVID-19  and their impact on the global economy, CELLINK is closely monitoring developments and is prepared  to take measures to reduce the risk of the company's continued development and expansion being long-term affected.


Due to travel restrictions, cancellations of exhibitions and difficulties in conducting demonstrations in customers' labs as many companies are restricting access to their facilities, the company sees a temporary change in the sales process that may affect demand for the company's products and services. The financial consequences are still difficult to estimate, but the company will continuously implement measures to limit the impact on company operations. The company currently intends to implement measures such as short-term lay-off and other general cost savings. Through these measures, we expect to be in a strong position to capitalize on the opportunities that exist in the market when countries and companies re-open.


For further information, please contact:

Erik Gatenholm, CEO                                                                 Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00                                       Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566                                               Phone (US): +1 (857) 332 2138

E-mail: [email protected]                                                              E-mail: [email protected]


This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 22, 2020 at 15:30 CET.


CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected]

Latest press releases
March 22, 2020RegulatoryUpdate regarding COVID-19
November 14, 2019Annual Report 2018/2019